Opinion|Videos|August 12, 2024
Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Advertisement
Episodes in this series
- Briefly discuss the latest evidence surrounding acquired BTKi resistance in CLL. What clinical insights do recent data provide?
- DrDAVIDS:ELEVATE-RR –
Woyach J et al. ICML 2023. Abstract 163 ;Poster 163 - (57:40 – follow up Q) invitro datanot hte end all be all.
- DrDAVIDS:ELEVATE-RR –
Dr Coombs to Group:What implications may these findings have on treatment sequencing? Is there a potential role of testing for acquired mutations upon disease progression?
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5